Articles tagged "Induction therapy"

2016 American Transplant Congress
B Cell Signature Profiling in Kidney Transplant Patients on Thymoglobulin.
A. Benitez,¹ T. Milford,² K. Torralba,³ K. Payne,² M. De Vera.¹
¹Transplantation Institute, Loma Linda University Health Care, Loma Linda, CA; ²Basic Science Division of Anatomy, Loma Linda University, Loma Linda, CA.
Purpose: B cell subsets could be used as biomarkers to modulate therapy regimens in kidney transplant patients. B cell subsets occur with varying proportions within…
2016 American Transplant Congress
Calcineurin Inhibitor (CNI) Delay with ATG Induction: Teaching an Old Dog, New Tricks.
A. Aliabadi,¹ J. Goekler,¹ O. Salameh,¹ T. Haberl,¹ B. Steinlechner,² P. Opfermann,² A. Kaider,¹ K. Uyanik-Uenal,¹ G. Laufer,¹ A. Zuckermann.¹
¹Cardiac Surgery, Medical University of Vienna, Vienna, Austria; ²Cardiothoracic and Vascular Anaesthisiology, Medical University of Vienna, Vienna, Austria.
CNI delay early after heart transplantation is a recommended therapeutic option according to ISHLT guidelines. However, there exist only few published data on feasibility of…
2016 American Transplant Congress
Alemtuzumab Induction Allows Better Rejection Free Graft Survival in Comparison to Basiliximab Although with Increased Post Transplant Viral Infections.
V. Siddagangaiah,¹ H. Sharma,² N. Lal,¹ J. Rai,¹ M. Howse,¹ D. Ridgway,¹ A. Sharma,¹ A. Hammad,¹ S. Mehra.¹
¹Renal Transplant Surgery, Royal Liverpool and Broadgreen University Hospital, Liverpool, United Kingdom; ²Transplant Surgery, Manchester Royal Infirmary, Manchester, United Kingdom.
Introduction: 3C study concluded that in comparison to basiliximab, alemtuzumab induction reduces the risk of biopsy proven acute rejection (BPAR) in renal transplant recipients. In…
2016 American Transplant Congress
Induction Therapy with Depleting Antibodies in Low Immunological Risk Renal Transplant Patients Treated with a Steroid Free Regimen – Comparison of Alemtuzumab vs. Antithymocyte Globulin.
N. Bossini,¹ S. Sandrini,¹ R. Tardanico,² F. Valerio,¹ G. Setti,¹ C. Salviani,¹ S. Possenti,¹ P. Foini,¹ E. Marta,¹ G. Cancarini.¹
¹Division and Chair of Nephrology, A.O "Spedali Civili" and University, Brescia, Italy; ²Division and Chair of II Laboratory of Pathology, A.O "Spedali Civili" and University, Brescia, Italy.
Induction therapy with depleting antibodies reduces rejection rate and potentially improves efficacy of steroid free regimens after renal transplantation.This prospective, single-centre, cohort study evaluated cumulative…
2016 American Transplant Congress
Basiliximab Induction for Safe Delay of Calcineurin Inhibitors in High MELD Liver Transplant Recipients.
J. Clark,¹ T. Sparkes,¹ B. Masters,¹ J. LaMattina,² R. Barth,² M. Moss.¹
¹University of Maryland Medical Center, Baltimore, MD; ²University of Maryland School of Medicine, Baltimore, MD.
Background: Available literature supports basiliximab induction for safe delay of CNI initiation and renal recovery; however there is a paucity of evidence for use in…
2016 American Transplant Congress
Antithymocyte (ATG) Dose Density in Renal Transplant Recipients (RTR) with Early Graft Dysfunction (EGD).
S. Kuten, S. Patel, R. Knight, D. Nguyen, E. Graviss, H. Podder, A. Gaber.
Houston Methodist Hospital, Houston, TX.
The cumulative amount of ATG for induction may be given as consecutive (cDD) or intermittent day dosages (iDD). iDD allows for leukocyte or platelet recovery…
2016 American Transplant Congress
Associations of Risk Factors and Kidney Retransplant Outcomes Vary Between Three Common Induction Agents: Results from the Analysis of Over Ten-Thousand Cases in Ten Years.
A. Santos, X. Wen, M. Casey, S. Rehman, K. Womer.
Medicine, University of Florida, Gainesville, FL.
BACKGROUND: There is no published study comparing the significance of risk factors for graft outcomes associated with common induction regimens combined with tacrolimus and mycophenolate…
2016 American Transplant Congress
Impact of Early Red Blood Cell Transfusion After Kidney Transplantation on De Novo HLA Sensitization in the Setting of Antithymocyte Globulin Induction.
T. Jouve,^1,2 G. Rigault,^1,2 B. Janbon,¹ R. Tetaz,¹ N. Terrier,¹ D. Masson,³ L. Rostaing,^1,2 P. Malvezzi.¹
¹Nephrology and Kidney Transplantation Unit, Grenoble University Hospital, Grenoble, France, Metropolitan; ²Grenoble Alpes University, Grenoble, France, Metropolitan; ³Etablissement Francais du Sang, Grenoble, France, Metropolitan.
Introduction:HLA specific antibodies detection (HSA) and that of Donor Specific Antibodies (DSA) were revolutionized by the introduction of solid phase assays (Luminex®), therefore making these…
2016 American Transplant Congress
Outcomes in Obese Renal Transplant Recipients Using High versus Low-Dose Thymoglobulin.
N. Jasiak,¹ C. Stromayer,¹ J. Thielke,¹ J. Chen,² J. Chen,¹ B. Talon,¹ R. Rubin-Tobar,¹ E. Benedetti,² P. West-Thielke.^1,2
¹Pharmacy, University of Illinois, Chicago; ²Transplant Surgery, University of Illinois, Chicago, IL.
Background: Dosing of rabbit anti-thymocyte globulin (rATG) induction in renal transplant recipients is highly variable by transplant center. Optimizing rATG dose becomes extremely important for…
2016 American Transplant Congress
Outcomes of Depleting Antibody Induction in Kidney Transplantation: A Paired Kidney Analysis.
M. Sampaio, B. Chopra, K. Sureshkumar.
Nephrology and Hypertension, Allegheny General Hospital, Pittsburgh, PA.
Induction therapy can improve graft survival following kidney transplantation. Organ quality, a major determinant of graft outcomes may act as a confounder in comparative studies…